sarpogrelate has been researched along with cyclic gmp in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Abe, Y; Fujisawa, Y; Kimura, S; Kondou, N; Kosaka, H; Nishiyama, A; Rahman, M; Tian, RX; Yoneyama, H; Zhou, MS | 1 |
Arockia Rani P, J; Fukatsu, A; Hayashi, T; Iguchi, A; Kano, H; Matsui-Hirai, H; Sumi, D; Tsunekawa, T | 1 |
2 other study(ies) available for sarpogrelate and cyclic gmp
Article | Year |
---|---|
DOI, a 5-HT2 receptor agonist, induces renal vasodilation via nitric oxide in anesthetized dogs.
Topics: Anesthesia; Animals; Cyclic GMP; Dogs; Enzyme Inhibitors; Female; Hemodynamics; Indophenol; Kidney; Male; NG-Nitroarginine Methyl Ester; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Nitrites; Receptors, Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Succinates; Vasodilation | 2002 |
Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism.
Topics: Acetylcholine; Animals; Antioxidants; Aorta, Thoracic; Biomarkers; Blood Proteins; Cholesterol, HDL; Coronary Artery Disease; Cyclic GMP; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Endothelium, Vascular; Hypercholesterolemia; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 2; Models, Cardiovascular; Myocardial Contraction; Myocytes, Smooth Muscle; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Rabbits; RNA, Messenger; Serotonin Antagonists; Succinates; Treatment Outcome; Vasodilator Agents; Vitamin E | 2003 |